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Dear Editor
We are grateful to the critical response from the reviewer. We have added response to the 7 
Comments from the reviewer . In the revised version the changes made in 2-7 are in yellow 
background.
We hope that the revised version can be published in SJG




1. The English needs to be corrected/edited. There are several grammatical mistakes, 
especially on the singular/plural form of the subject/predicate.
Response: The English language has been improved in the revised manuscript by a competent 
native English person.
2. I am worried about the confounding factors in the immunological status of the subjects. 
Were all the immunological illnesses excluded? How "severe  chronic disease" is defined on 
page 6, row 112.
Response: Severe chronic diseases were excluded including severe immunological diseases 
such as rheumatoid, Bechterew, SLE etc. The severe diseases were based diagnosis in the 
patients medical record and on well-documented and accepted international criteria. We fully 
agree with the critic and the content of severe disease is more detailed described in the revised 
version.  
3.  Are all the inclusion and exclusion criteria explained in the paper?
Response: We agree that the mandatory inclusion and exclusion criteria are suboptimal 
presented. In short, the logistics were as followed: there was a screening of patients 
performing a coloscopi and recruited were patients that fulfilled Rome II criteria for IBS 
diagnosis. Then the next step was the ordinary management of patients with IBS: exclusion of 
other GI diseases. This included as described, blood tests, stool samples, breath tests, 
endoscopy, histological examination, X-ray, or ultrasound investigations to exclude organic 
disease or other malabsorption diseases including lactose intolerance
These extra investigation were not mandatory except for blood test, and performed when only 
judged as actual by the clinician. Therefore, one exclusion criteria was other GI diseases. In 
addition as described Patients with post-infectious IBS were excluded. If patients did meet 
Rome II criteria for diagnosis of IBS and other GI diseases and severe chronic disease were 
excluded, they were invited to participate in the study as the IBS group. In the revised version 
standard screening laboratory test including transglutaminase was performed, 
The revised version is changed to a more optimal and readable describing inclusion and 
exclusion criteria. 
4. The authors write that the individual diagnostic workup was not mandatory. What were the 
exclusion criteria? How could they be excluded if the laboratory analyses were not 
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mandatory? Why was the "individual diagnostic workup" done if it was not at all used in 
analyzing the results?
-Only fructose intolerance test was performed. What about other intolerances (like lactose) 
and allergies - again if the tests were not mandatory?             
Response: The logistics are described and commented above, According to the question of 
food allergy and lactose intolerance. the patients were carefully asked for food allergy and 
lactose intolerance and were excluded if typical symptoms. In cases of uncertainty food 
allergy blood tests and lactose intolerance test were performed. In the revised version this is 
implemented
5. Dietary intake (content and timing) was not evaluated (e.g. fiber intake vs bloating). It 
could be a confounding factor.
Response: The patients were told to use their ordinary food intake but a more defined diet 
intake including fiber content would definitely given more comprehensible data. If this lack 
represents a confounding factor and/or a causal factor is questionable. Anyhow, this is 
implemented in the Discussion of microbiota potential effect on our inflammation markers- 
see point 7.
6.  FRD should be in the abbreviation list or explained in the text. It is a bit surprising that 
there were no mixed type of IBS.
Response: FRD added both in the abbreviation list. As described in the text: All IBS patients 
had a combination of diarrhea and constipation so subgrouping could not be performed
7. The possible role of diet and intestinal microbiota on the inflammation markers could be 
shortly discussed.
Response: added in Discussion, last paragraph
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45 ABSTRACT
46 Background: It has been proposed that irritable bowel syndrome (IBS) is as a low-grade 
47 mucosal inflammatory disease.
48 Objective: To characterize the intestinal inflammatory profile in IBS patients with or without 
49 fructose intolerance.  
50 Design: Patients referred to colonoscopy with IBS complaints were screened for participation. 
51 IBS patients diagnosed according to the Rome II criteria and with no organic gastrointestinal 
52 disease were included in the study. One subgroup was patients included in a fructose-reduced 
53 diet study for 2 months with effects based on VAS symptom scores. Healthy controls were 
54 subjects under investigation of colorectal cancer screening with no IBS or other 
55 gastrointestinal diseases. All patients included had normal histology from rectum. Mucosal 
56 cytokines, chemokines and growth factors were measured by multiplex technology. 
57 Results: Of 27 inflammatory markers tested in the mucosal tissue, 13 were significantly 
58 increased and none was significantly decreased in IBS as compared to controls. Significantly 
59 increased were the proinflammatory cytokines tumor necrosis factor, the typical TH1 markers 
60 IFNγ, IL-1β, IL-2 and RANTES, the typical TH2 markers IL-5 and IL-9, the TH17 marker 
61 IL-17, TNF, the pleiotropic IL-15, and the growth factors bFGF and GM-CSF. In IBS patients 
62 with fructose intolerance only IL-5 was significantly increased compared to patients without 
63 fructose intolerance. 
64 Conclusion: A dysregulated mucosal inflammatory profile with an increased level of TH1, 
65 TH2 and TH17 markers, and growth factors were observed in bowel mucosa in of IBS 
66 patients when compared to healthy controls.
67
68
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70 1. Introduction 
71 Irritable bowel syndrome (IBS) is characterized as a functional disease as there are no well-
72 documented causal pathophysiological mechanisms. Typically, in IBS there is a 
73 hypersensitivity with low response threshold to various external stimuli, first documented by 
74 Ritchie J in 1973 [1]. This hypersensitivity of afferent neurons is activated by stimuli such as 
75 distension of hollow organs and chemical mediators such as proinflammatory and lipotoxic 
76 molecules (for review, see reference [2]). The underlying mechanisms behind visceral 
77 hypersensitivity in IBS is unknown, but the most referred hypothesis is that the visceral 
78 hypersensitivity in IBS is caused by an aberrant neuroimmune interaction (for review, see [2-
79 7]).  
80       One of the first reports suggesting IBS as a low-grade mucosal inflammatory disease was 
81 by Collins in 1992 [8], but this hypothesis is still controversial [9]. Two features support this 
82 hypothesis: IBS is frequently seen both after a gastrointestinal infection [10] and in 
83 inflammatory bowel disease in remission [11].  However, the documentation of visceral 
84 hypersensitivity as a neuroimmune dysregulation in IBS is poor. At the level of mucosal 
85 immune cells, several reports describing increased number of T lymphocytes [12-14], mast 
86 cells [15,16], and degranulated mast cells [14,17]. Somewhat contradictory, decreased levels 
87 of T cells and mast cells have been reported [18] in post infectious and classical IBS. 
88 Moreover, various results have been reported for cytokines and chemokines at mucosal level: 
89 increased transcript levels of IL-1β [19] has been reported, decreased transcript levels were 
90 observed for IL-10 [20,21] and for the chemokines IL-8, CXCL-9 and MCP1 [22], an 
91 imbalance between TH1 and TH2 cytokines was observed [23], whereas no changes were 
92 observed for the proinflammatory TNF alpha, IL-6 and IL-beta [22]. Finally, in contrast to 
93 these reports, no significant differences between classical, non-postinfectious IBS and healthy 
94 control were found neither at the mucosal levels of immune cells nor at transcript levels 
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95 [24,25]. Taken together, there are contradictory reports concerning the type of immune 
96 dysregulation involved if IBS can be explained as a low-grade inflammatory bowel disease. 
97       The aim of this study was to identify the inflammatory profile of various relevant 
98 cytokines, chemokines and growth factors in colon biopsies from patients with IBS, including 
99 the subgroup with self-reported fructose intolerance, compared to healthy controls.   
100
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102 2. Materials and methods
103 2.1. Subject groups
104 The patients were recruited from three cohorts: from patients referred to colonoscopy due to 
105 IBS symptoms, from the FINN study (Fructose malabsorption In North Norway, [25] 26, 
106 Berg 2013), and patients in colorectal cancer screening. The recruited patients were first 
107 interviewed for a complete medical record to ensure they fulfilled Rome II criteria for IBS 
108 diagnosis. The inclusion criteria were patients who fulfilled Rome II criteria and were willing 
109 to participate. They then underwent an individual diagnostic workup including, but not 
110 mandatory, blood tests, stool samples, breath tests, endoscopy, histological examination, X-
111 ray, or ultrasound investigations to exclude organic disease or other malabsorption diseases 
112 including lactose intolerance and food allergy. A standard screening laboratory test including 
113 test for celiac disease was performed. According to the question of food allergy and lactose 
114 intolerance, the patient were carefully asked for food allergy and lactose intolerance and were 
115 excluded if typical symptoms. In some cases with uncertainty, food allergy blood tests and 
116 lactose breath test were performed. The exclusion criteria were patients with other 
117 gastrointestinal diseases, including post-infectious IBS, use of laxatives due to constipation, 
118 patients with severe medical disorders such as diabetes mellitus, cancer, severe cerebral, lung 
119 or heart diseases and finally patients with severe immunological diseases such as rheumatoid 
120 arthritis, SLE etc. A subgroup of the IBS patients were further included in the FINN study. 
121 They performed a diagnostic test for self-reported dietary fructose intolerance (12-week 
122 fructose reduced diet (FRD) followed by 1 week high-fructose provocation test) [27].  Finally, 
123 patients with no IBS symptoms according to Rome II criteria represented the healthy control 
124 group. All patients performed colonoscopy, 20 biopsies were obtained from rectum and stored 
125 at – 70℃ until analysis. Biopsies were also obtained for ordinary histological examinations 
126 (haematoxylin and eosin staining). The IBS group and the healthy control group were 
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127 included in the study if no endoscopic nor histological sign of pathology, and no other 
128 gastrointestinal disease including post-infectious IBS and severe medical disorders. Moreover, 
129 in all subjects, VAS registrations for pain and bloating (0-100 mm, 0 mm for no symptoms 
130 and 100 mm for maximal symptom score) were performed, and the number of stools and 
131 registration of stool quality on a scale from 1-7 (Bristol scale [27]).
132
133 2.2. Analyses of cytokines, chemokines and growth factors
134 The mucosal profile of various relevant cytokines, chemokines and growth factors were 
135 determined by multiplex technology. Homogenization of tissue was performed with the 
136 following protocol: A mix of 495 µL CytoBuster Protein Extraction Reagent (Novagen, San 
137 Diego, CA) and 5 µL Protease Inhibitor cocktail set 1 (Calbiochem, Darmstadt, Germany) 
138 was added to 50 mg of tissue sample and homogenized with Xiril Dispomix. After 
139 completion, the samples were incubated for five minutes on ice and thereafter centrifuged at 
140 2,500 x g for 20 minutes at 4 °C. The supernatants were transferred to Nunc tubes and stored 
141 at -70°C. The samples were analyzed using a multiplex cytokine assay (Bio-Plex Human 
142 Cytokine 27-Plex Panel; Bio-Rad Laboratories Inc., Hercules, CA, USA) containing the 
143 following interleukins, chemokines and growth factors:  Interleukin (IL)-1β, IL-1 receptor 
144 antagonist (IL1-ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, 
145 IL-17, eotaxin, basic fibroblast growth factor (bFGF), granulocyte-colony stimulating factor 
146 (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), interferon (IFN)-γ, 
147 interferon-inducible protein (IP-10),  monocyte chemotactic protein (MCP-1), macrophage 
148 inflammatory protein (MIP)-1α, MIP-1β, platelet derived growth factor-BB (PDGF-BB), 
149 regulated upon activation T cell expressed and secreted  (RANTES), tumor necrosis factor 
150 (TNF), and vascular endothelial growth factor (VEGF). The samples were analyzed on a 
151 Multiplex Analyzer (Bio-Rad Laboratories) according to instructions from the manufacturer.
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152
153 2.3. Ethics and registrations
154 The study was approved by the Regional Committee of Medical Ethics North Norway (ID: 
155 136/2006), and the study was registered in clinicaltrials.gov NCT00555191
156
157
158 2.4. Statistical analysis
159 Baseline characteristics and individual mediator measurements were explored using 
160 parametric tests; in most cases it was necessary to perform a logarithmic transformation to 
161 obtain a normal distribution. Chi-square test was used for contingency tables. A principal 
162 component analysis was performed on the mediator readings from all subject groups. Further 
163 details in the result section. 
164
165 3. Results
166 3.1. Subject groups
167 A total of 42 IBS patients were included, 14 patients performing fructose reduced diet (FRD) 
168 where 8 patients had fructose intolerance based on the criteria of effect of fructose restricted 
169 diet (< 2 g fructose/meal) and positive provocation test on fructose-rich meals [27] and 6 
170 patients had no fructose intolerance. All IBS patients had a combination of diarrhea and 
171 constipation so subgrouping could not be performed. The demographics are shown in table 1. 
172
173 3.2. Mucosal intestinal inflammatory profiles in IBS patients versus healthy controls
174 Of the 27 mediators measured, 13 was significantly (p<0.05) increased and none were 
175 decreased in the IBS patients compared to controls (Table 2).
176 3.3. Cytokines
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177 Most of the proinflammatory cytokines were increased at significant levels such as the TH1 
178 cytokines INFγ , IL-1β,  IL-2, the pleiotropic IL-15, the TH17 cytokine IL-17, TNF, but not 
179 IL-6, IL-7 or IL-8. The TH2 cytokines IL-4 and IL-9, but not IL-5, was significantly increased 
180 compared to the healthy control group (table 2).
181 3.4. Chemokines
182 Of the chemokines analyzed, only RANTES and Eotaxin were significantly increased when 
183 compared to the control group (table 2).
184 3.5. Growth factors
185 Of the various growth factors analyzed, bFGF, PDGFBB, and GM-CSF were significantly 
186 increased, but not the other growth factors when compared to the control group (table 2).  
187
188 3.6. Intestinal immune profile in subgroups of IBS
189 IL-5 was significantly increased in IBS pati nts with self-reported fructose intolerance only 
190 (0.4 pg/mL [0.2 – 0.6] n=6) compared to patients without fructose intolerance (0.1 pg/mL [0.0 
191 – 0.3] n=8) P= 0.02 (data not shown for the rest).
192
193        3.7.   Principal component analysis
194 Principal component analysis of the dataset extracted 3 components with a cumulative 
195 explained variance of 55% (KMO 0.69; Bartlett's test of sphericity Chi-square = 1835; df = 
196 351; P = 4.9 E-199). The rotated solution showed that PC1 (30 % variance explained) had 
197 highest factor loadings on the mediators TNF, IL-4, IFNγ, IL-17 and IL-2 corresponding to a 
198 pro-inflammatory cytokine axis. PC2 (13 % variance explained) had highest factor loadings 
199 on IL-8, IL-6, IL-9, FGF basic, and MIP-1α corresponding to a pro-inflammatory chemokine 
200 axis. Finally, PC3 (11 % variance explained) had highest loadings on VEGF, IL-10, IL-12 
201 (p70), IL-7, and IL-5 the direction of which is not entirely clear. Figure 1 shows factor 
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202 loadings of PC1 and PC2 for the individual observations in the study groups. Many IBS 
203 subjects are located among the normal controls. However, some degree of immune activation 
204 may exist in subgroups of IBS. 
205
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207 4. Discussion
208 In this study, we have found increased mucosal levels of proinflammatory TH1 cytokines 
209 IFN-γ, IL-1b, 1L-2; the TH1 chemokine RANTES, the TH 17 cytokine IL-17cytokine, the 
210 TH2 and allergy -associated cytokines IL-5, TNF and IL-9; the growth factors FGF basic and 
211 GM-CSF, when compared to healthy control without IBS symptoms. Our study indicates that 
212 in IBS with no sign of infiltrating leucocytes at HE histology examinations represents a 
213 disease of immune dysregulation whereas an apparent minor immune dysregulation may be 
214 due to the fructose intolerance.
215      The mucosal levels of some of the mucosal cytokines TH1, TH2 and TH17 were 
216 significantly increased in IBS compared to the healthy control group. These cytokines which 
217 is generally increased in IBD, although at much higher levels, has to some extent been studied 
218 in IBS [28,29]. Thus, various differences to mucosal levels in healthy controls have been 
219 reported in some publications [19,23,30] but not in others [21,24,25]. Also of interest to note 
220 was the mucosal TNF as one of the main mediators of IBD [28], was increased in this study 
221 but not in other studies [20,22]. This may be due to methodological differences, especially 
222 considering the low-level increase registered. The TNF-alpha G/A polymorphism at position 
223 308 has been observed in IBS patients [31] and may have pathophysiological role in IBS.  
224      The two TH2 cytokines IL-5 and IL-9 were increased compared to the healthy control 
225 group. Both cytokines secreted from mast cells that has been proposed to be one of the main 
226 mediators of hypersensitivity in IBS [32]. Our IL-5 and IL9 data are in agreement with 
227 previous reports in IBS [33,34]. Therefore, all these data taken together indicate that in IBS a 
228 mucosal TH2 dysregulation exists, which mediates a low-grade inflammation with activation 
229 of inflammatory cells such as mast cells [3,32].
230       The mucosal level of the TH1 chemokine RANTES and eotaxin was significantly 
231 increased in IBS. First, the eotaxin result fits well with the documentation of mast cell 
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232 activation in IBS [16] and the mast cell activation of eotaxin [35]. Moreover, our data agrees 
233 with our findings of increased levels of the TH1 cytokines and TNF as cytokines with strong 
234 effect on activation of chemotaxis. In another report, CXCL-9 and MCP1 were even lower in 
235 IBS than in the healthy controls [22]. These discrepancies are hard to explain. The 
236 chemokines are responsible for the leukocyte migration by creating a chemical gradient from 
237 the vascular endothelium to the infected cells and by selective expressions of different 
238 chemokine receptors on the leukocytes [36]. It is interesting to speculate that a lack of a more 
239 complete and global chemokine response may be one explanation of the lack of a tissue 
240 invasion of leucocytes measured by conventional diagnostic procedures.  
241      Of the various growth factors measured, there were significant increases in the growth 
242 factors bFGF, PDGFBB and GM-CSF. As far as we know there are no previous reports of 
243 these two mucosal growth factors in IBS. Other growth factors such as neural growth factor 
244 has been shown to be overexpressed in intestinal mucosa in IBS [37]. In general, growth 
245 factors play a role to maintain the mucosa integrity [38] are proposed to have anti-
246 inflammatory effects. In chronic inflammation such as in IBD, these mediators play a role in 
247 the mucosal healing. 
248      In IBS patients with self-reported fructose intolerance, only IL-5 was significantly 
249 increased compared to IBS patients without fructose intolerance indicating a possible allergy-
250 like mechanism. The pathophysiological mechanisms behind this condition is unknown, but it 
251 has been proposed to be due to reduced intestinal absorption capacity of fructose [39]. 
252 Whether an allergic mechanism could be involved, has to be further investigated.
253     In general, IBS is most likely a heterogeneous disease where the main proposed 
254 contributing pathophysiological factors are neuroendocrine abnormalities, low grade 
255 inflammation, failure of the gut barrier, increased fecal bile content, abnormal visceral 
256 hypersensitivity and psychosocial stress. Moreover, stress as a causal factor of immune 
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257 dysregulation in the gut has been known for long in animals [40] and in humans (for review, 
258 see [41]. The heterogeneity is supported by the various contradictory reports concerning the 
259 mucosal immunophenotype between our and other reports (for review, see [4,7,42,43]. The 
260 pathophysiological mechanism behind IBS can either be abnormal interactions between 
261 neurons/nerves and immune cells [43], also referred to as the “neuroimmune” synapse [6]. 
262 Moreover, though many of the IBS subjects in the present study show a pro-inflammatory 
263 tendency, a substantial part of the IBS subjects falls within the “normal control” sphere 
264 (figure 1), which underlines the impression that IBS is a disorder of heterogenic pathogenesis. 
265 Finally, we should be aware that the suggested immunological disturbancies in IBS is still 
266 least controversial and described by some as a possible myth [44]. 
267      The strength of this study is the broad mucosal characterization of cytokines, chemokines 
268 and growth factors that would be potentially involved in IBS as an immunological active 
269 disease.  The weakness of the study that should initiate further studies is that whole biopsy 
270 extracts is relatively crude. A mucosal immunologic characterization at cellular level would 
271 give more comprehensive data. Moreover, IBS is most likely a heterogeneous disease 
272 concerning the potential etiological factors and the various clinical phenotypes.  Therefore, 
273 further studies are needed focusing on subgrouping defined by subgroup phenotypes of IBD, 
274 as well as precipitating factors such as infection, stress and antibiotics. Moreover, potentially, 
275 the inflammatory biomarkers could be explained by changes in the fecal microbiota, and 
276 microbiotic phenotypes related to diet including fiber intake [45,46]. This awaits further 
277 studies.
278
279       In conclusion, a dysregulated mucosal immune profile with a mixed TH1, TH2, TH17 and 
280 growth factor profile is observed in IBS patients when compared to healthy control. This 
281 indicates that IBS is a low-grade inflammatory bowel disease with an apparent incomplete 
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282 chemotactic stimulus that may preclude recruitment of leucocytes from the general 
283 circulation.      
284
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425
426 Table 1 










Age (median [range]) 48.5 50 [40  72] 48 [25  62] 59 [35  79] Ns
Female per cent 68 % 63 % 100 % 35 % 0.019#
Abdominal pain/discomfort (mm) 55.2 61 50 0 Ns*
Bloating (mm) 56 63 51 0 Ns*
Stool frequency (median [range]) 1.8 1.6 1.7 1.0 Ns*
Boston scale stool consistency 
(mean [range])
4,6 5.2 3.9 4.0 Ns*
428 FI: Fructose intolerance. FT: fructose tolerance. IBS: Irritable bowel syndrome. # Controls vs 
429 IBS groups; * IBS subgroups compared.
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431 Table 2. Mucosal levels of cytokines, chemokines and growth factors in patients with IBS and 
432 in healthy controls. 
Mediator IBS (N = 42) Normal control (N = 20) P
IFNγ 18 (16 – 20) 14 (12 – 17) 0.010
IL-1β 6.7 (5.6 – 7.9) 4.1 (3.1 – 5.5) 0.004
IL-1RA 1299 (1012 – 1668) 818 (533 – 1254) 0.057
IL-2 0.64 (0.58 – 0.71) 0.39 (0.35 – 0.44) <0.0005
IL-4 0.91 (0.79 – 1.04) 0.71 (0.62 – 0.82) 0.032
IL-5† 0.29 (0.25 – 0.33) 0.33 (0.22 – 0.43) 0.435
IL-6 1.5 (1.1 – 2.0) 1.1 (0.9 – 1.2) 0.136
IL-7 10.7 (9.7 – 11.9) 10.6 (9.2 – 12.2) 0.893
IL-8 24 (16 – 35) 15 (11 – 19) 0.101
IL-9 8.2 (7.2 – 9.2) 6.5 (5.7 – 7.5) 0.040
IL-10 5.5 (4.7 – 6.4) 4.6 (3.8 – 5.5) 0.165
IL-12p70 5.8 (4.9 – 6.9) 5.2 (4.5 – 6.1) 0.404
IL-13 0.85 (0.79 – 0.91) 0.81 (0.73 – 0.90) 0.448
IL-15 2.3 (2.1 – 2.6) 1.7 (1.5 – 1.8) <0.0005
IL-17† 3.2 (2.6 – 3.7) 2.0 (1.6 – 2.4) 0.001*
TNF 160 (143 – 178) 130 (115 – 147) 0.025
Eotaxin 6.7 (5.6 – 7.9) 4.1 (3.1 – 5.5) 0.004
IP-10 590 (437 – 798) 401 (301 – 533) 0.119
MCP1MCA 75 (66 – 86) 71 (60 – 85) 0.647
MIP-1α 3.3 (2.6 – 4.2) 3.0 (2.3 – 4.0) 0.645
MIP-1β 74 (62 – 89) 64 (53 – 77) 0.321
RANTES 2011 (1378 – 2934) 891 (545 – 1454) 0.016
bFGF 674 (596 – 761) 446 (384 – 518) <0.0005
G-CSF 6.4 (5.0 – 8.2) 6.4 (5.2 – 8.0) 0.966
GM-CSF 4.4 (3.8 – 5.1) 2.4 (1.7 – 3.1) <0.0005
PDGFBB 11.7 (9.9 – 13.7) 8.2 (6.1 – 11.1) 0.032
VEGF 160 (130 – 196) 150 (117 – 192) 0.722
433 Values are mean (95% CI of mean) expressed in pg/mL of tissue supernatant. Logarithmic 
434 transformation was applied to obtain Gaussian distribution in all cases except those marked 
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435 with dagger. P-values were generated by independent samples t-test; equality of variances 
436 were observed in all cases except IL17 where the corrected t was used (*).
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438 Figure 1. Principal component analysis of 27-plex mediator measurement in rectal mucosa 
439 from subjects with IBS w/wo fructose intolerance, IBS controls, and normal controls. Three 
440 PC’s were extracted accounting for a cumulated 55% of the variance. The plot shows 
441 individual factor loadings of the two first components in a rotated solution. PC1 (30% 
442 variance) represents an adaptive pro-inflammatory component with high contribution from 
443 mediators like TNF, IFNγ, IL-17, IL-4, and IL-2. PC2 (13% variance) represents an early 
444 response pro-inflammatory component with high contribution from mediators like IL-8, IL-6, 
445 IL-9, bFGF, and MIP-1α. 
446
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45 ABSTRACT
46 Background: It has been proposed that irritable bowel syndrome (IBS) is as a low-grade 
47 mucosal inflammatory disease.
48 Objective: To characterize the intestinal inflammatory profile in IBS patients with or without 
49 fructose intolerance.  
50 Design: Patients referred to colonoscopy with IBS complaints were screened for participation. 
51 IBS patients diagnosed according to the Rome II criteria and with no organic gastrointestinal 
52 disease were included in the study. One subgroup was patients included in a fructose-reduced 
53 diet study for 2 months with effects based on VAS symptom scores. Healthy controls were 
54 subjects under investigation of colorectal cancer screening with no IBS or other 
55 gastrointestinal diseases. All patients included had normal histology from rectum. Mucosal 
56 cytokines, chemokines and growth factors were measured by multiplex technology. 
57 Results: Of 27 inflammatory markers tested in the mucosal tissue, 13 were significantly 
58 increased and none was significantly decreased in IBS as compared to controls. Significantly 
59 increased were the proinflammatory cytokines tumor necrosis factor, the typical TH1 markers 
60 IFNγ, IL-1β, IL-2 and RANTES, the typical TH2 markers IL-5 and IL-9, the TH17 marker 
61 IL-17, TNF, the pleiotropic IL-15, and the growth factors bFGF and GM-CSF. In IBS patients 
62 with fructose intolerance only IL-5 was significantly increased compared to patients without 
63 fructose intolerance. 
64 Conclusion: A dysregulated mucosal inflammatory profile with an increased level of TH1, 
65 TH2 and TH17 markers, and growth factors were observed in bowel mucosa in of IBS 
66 patients when compared to healthy controls.
67
68
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70 1. Introduction 
71 Irritable bowel syndrome (IBS) is characterized as a functional disease as there are no well-
72 documented causal pathophysiological mechanisms. Typically, in IBS there is a 
73 hypersensitivity with low response threshold to various external stimuli, first documented by 
74 Ritchie J in 1973 [1]. This hypersensitivity of afferent neurons is activated by stimuli such as 
75 distension of hollow organs and chemical mediators such as proinflammatory and lipotoxic 
76 molecules (for review, see reference [2]). The underlying mechanisms behind visceral 
77 hypersensitivity in IBS is unknown, but the most referred hypothesis is that the visceral 
78 hypersensitivity in IBS is caused by an aberrant neuroimmune interaction (for review, see [2-
79 7]).  
80       One of the first reports suggesting IBS as a low-grade mucosal inflammatory disease was 
81 by Collins in 1992 [8], but this hypothesis is still controversial [9]. Two features support this 
82 hypothesis: IBS is frequently seen both after a gastrointestinal infection [10] and in 
83 inflammatory bowel disease in remission [11].  However, the documentation of visceral 
84 hypersensitivity as a neuroimmune dysregulation in IBS is poor. At the level of mucosal 
85 immune cells, several reports describing increased number of T lymphocytes [12-14], mast 
86 cells [15,16], and degranulated mast cells [14,17]. Somewhat contradictory, decreased levels 
87 of T cells and mast cells have been reported [18] in post infectious and classical IBS. 
88 Moreover, various results have been reported for cytokines and chemokines at mucosal level: 
89 increased transcript levels of IL-1β [19] has been reported, decreased transcript levels were 
90 observed for IL-10 [20,21] and for the chemokines IL-8, CXCL-9 and MCP1 [22], an 
91 imbalance between TH1 and TH2 cytokines was observed [23], whereas no changes were 
92 observed for the proinflammatory TNF alpha, IL-6 and IL-beta [22]. Finally, in contrast to 
93 these reports, no significant differences between classical, non-postinfectious IBS and healthy 
94 control were found neither at the mucosal levels of immune cells nor at transcript levels 
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95 [24,25]. Taken together, there are contradictory reports concerning the type of immune 
96 dysregulation involved if IBS can be explained as a low-grade inflammatory bowel disease. 
97       The aim of this study was to identify the inflammatory profile of various relevant 
98 cytokines, chemokines and growth factors in colon biopsies from patients with IBS, including 
99 the subgroup with self-reported fructose intolerance, compared to healthy controls.   
100
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102 2. Materials and methods
103 2.1. Subject groups
104 The patients were recruited from three cohorts: from patients referred to colonoscopy due to 
105 IBS symptoms, from the FINN study (Fructose malabsorption In North Norway, [25] 26, 
106 Berg 2013), and patients in colorectal cancer screening. The recruited patients were first 
107 interviewed for a complete medical record to ensure they fulfilled Rome II criteria for IBS 
108 diagnosis. The inclusion criteria were patients who fulfilled Rome II criteria and were willing 
109 to participate. They then underwent an individual diagnostic workup including, but not 
110 mandatory, blood tests, stool samples, breath tests, endoscopy, histological examination, X-
111 ray, or ultrasound investigations to exclude organic disease or other malabsorption diseases 
112 including lactose intolerance and food allergy. A standard screening laboratory test including 
113 test for celiac disease was performed. According to the question of food allergy and lactose 
114 intolerance, the patient were carefully asked for food allergy and lactose intolerance and were 
115 excluded if typical symptoms. In some cases with uncertainty, food allergy blood tests and 
116 lactose breath test were performed. The exclusion criteria were patients with other 
117 gastrointestinal diseases, including post-infectious IBS, use of laxatives due to constipation, 
118 patients with severe medical disorders such as diabetes mellitus, cancer, severe cerebral, lung 
119 or heart diseases and finally patients with severe immunological diseases such as rheumatoid 
120 arthritis, SLE etc. A subgroup of the IBS patients were further included in the FINN study. 
121 They performed a diagnostic test for self-reported dietary fructose intolerance (12-week 
122 fructose reduced diet (FRD) followed by 1 week high-fructose provocation test) [27].  Finally, 
123 patients with no IBS symptoms according to Rome II criteria represented the healthy control 
124 group. All patients performed colonoscopy, 20 biopsies were obtained from rectum and stored 
125 at – 70℃ until analysis. Biopsies were also obtained for ordinary histological examinations 
126 (haematoxylin and eosin staining). The IBS group and the healthy control group were 
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127 included in the study if no endoscopic nor histological sign of pathology, and no other 
128 gastrointestinal disease including post-infectious IBS and severe medical disorders. Moreover, 
129 in all subjects, VAS registrations for pain and bloating (0-100 mm, 0 mm for no symptoms 
130 and 100 mm for maximal symptom score) were performed, and the number of stools and 
131 registration of stool quality on a scale from 1-7 (Bristol scale [27]).
132
133 2.2. Analyses of cytokines, chemokines and growth factors
134 The mucosal profile of various relevant cytokines, chemokines and growth factors were 
135 determined by multiplex technology. Homogenization of tissue was performed with the 
136 following protocol: A mix of 495 µL CytoBuster Protein Extraction Reagent (Novagen, San 
137 Diego, CA) and 5 µL Protease Inhibitor cocktail set 1 (Calbiochem, Darmstadt, Germany) 
138 was added to 50 mg of tissue sample and homogenized with Xiril Dispomix. After 
139 completion, the samples were incubated for five minutes on ice and thereafter centrifuged at 
140 2,500 x g for 20 minutes at 4 °C. The supernatants were transferred to Nunc tubes and stored 
141 at -70°C. The samples were analyzed using a multiplex cytokine assay (Bio-Plex Human 
142 Cytokine 27-Plex Panel; Bio-Rad Laboratories Inc., Hercules, CA, USA) containing the 
143 following interleukins, chemokines and growth factors:  Interleukin (IL)-1β, IL-1 receptor 
144 antagonist (IL1-ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, 
145 IL-17, eotaxin, basic fibroblast growth factor (bFGF), granulocyte-colony stimulating factor 
146 (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), interferon (IFN)-γ, 
147 interferon-inducible protein (IP-10),  monocyte chemotactic protein (MCP-1), macrophage 
148 inflammatory protein (MIP)-1α, MIP-1β, platelet derived growth factor-BB (PDGF-BB), 
149 regulated upon activation T cell expressed and secreted  (RANTES), tumor necrosis factor 
150 (TNF), and vascular endothelial growth factor (VEGF). The samples were analyzed on a 
151 Multiplex Analyzer (Bio-Rad Laboratories) according to instructions from the manufacturer.
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152
153 2.3. Ethics and registrations
154 The study was approved by the Regional Committee of Medical Ethics North Norway (ID: 
155 136/2006), and the study was registered in clinicaltrials.gov NCT00555191
156
157
158 2.4. Statistical analysis
159 Baseline characteristics and individual mediator measurements were explored using 
160 parametric tests; in most cases it was necessary to perform a logarithmic transformation to 
161 obtain a normal distribution. Chi-square test was used for contingency tables. A principal 
162 component analysis was performed on the mediator readings from all subject groups. Further 
163 details in the result section. 
164
165 3. Results
166 3.1. Subject groups
167 A total of 42 IBS patients were included, 14 patients performing fructose reduced diet (FRD) 
168 where 8 patients had fructose intolerance based on the criteria of effect of fructose restricted 
169 diet (< 2 g fructose/meal) and positive provocation test on fructose-rich meals [27] and 6 
170 patients had no fructose intolerance. All IBS patients had a combination of diarrhea and 
171 constipation so subgrouping could not be performed. The demographics are shown in table 1. 
172
173 3.2. Mucosal intestinal inflammatory profiles in IBS patients versus healthy controls
174 Of the 27 mediators measured, 13 was significantly (p<0.05) increased and none were 
175 decreased in the IBS patients compared to controls (Table 2).
176 3.3. Cytokines
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177 Most of the proinflammatory cytokines were increased at significant levels such as the TH1 
178 cytokines INFγ , IL-1β,  IL-2, the pleiotropic IL-15, the TH17 cytokine IL-17, TNF, but not 
179 IL-6, IL-7 or IL-8. The TH2 cytokines IL-4 and IL-9, but not IL-5, was significantly increased 
180 compared to the healthy control group (table 2).
181 3.4. Chemokines
182 Of the chemokines analyzed, only RANTES and Eotaxin were significantly increased when 
183 compared to the control group (table 2).
184 3.5. Growth factors
185 Of the various growth factors analyzed, bFGF, PDGFBB, and GM-CSF were significantly 
186 increased, but not the other growth factors when compared to the control group (table 2).  
187
188 3.6. Intestinal immune profile in subgroups of IBS
189 IL-5 was significantly increased in IBS pati nts with self-reported fructose intolerance only 
190 (0.4 pg/mL [0.2 – 0.6] n=6) compared to patients without fructose intolerance (0.1 pg/mL [0.0 
191 – 0.3] n=8) P= 0.02 (data not shown for the rest).
192
193        3.7.   Principal component analysis
194 Principal component analysis of the dataset extracted 3 components with a cumulative 
195 explained variance of 55% (KMO 0.69; Bartlett's test of sphericity Chi-square = 1835; df = 
196 351; P = 4.9 E-199). The rotated solution showed that PC1 (30 % variance explained) had 
197 highest factor loadings on the mediators TNF, IL-4, IFNγ, IL-17 and IL-2 corresponding to a 
198 pro-inflammatory cytokine axis. PC2 (13 % variance explained) had highest factor loadings 
199 on IL-8, IL-6, IL-9, FGF basic, and MIP-1α corresponding to a pro-inflammatory chemokine 
200 axis. Finally, PC3 (11 % variance explained) had highest loadings on VEGF, IL-10, IL-12 
201 (p70), IL-7, and IL-5 the direction of which is not entirely clear. Figure 1 shows factor 
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202 loadings of PC1 and PC2 for the individual observations in the study groups. Many IBS 
203 subjects are located among the normal controls. However, some degree of immune activation 
204 may exist in subgroups of IBS. 
205
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207 4. Discussion
208 In this study, we have found increased mucosal levels of proinflammatory TH1 cytokines 
209 IFN-γ, IL-1b, 1L-2; the TH1 chemokine RANTES, the TH 17 cytokine IL-17cytokine, the 
210 TH2 and allergy -associated cytokines IL-5, TNF and IL-9; the growth factors FGF basic and 
211 GM-CSF, when compared to healthy control without IBS symptoms. Our study indicates that 
212 in IBS with no sign of infiltrating leucocytes at HE histology examinations represents a 
213 disease of immune dysregulation whereas an apparent minor immune dysregulation may be 
214 due to the fructose intolerance.
215      The mucosal levels of some of the mucosal cytokines TH1, TH2 and TH17 were 
216 significantly increased in IBS compared to the healthy control group. These cytokines which 
217 is generally increased in IBD, although at much higher levels, has to some extent been studied 
218 in IBS [28,29]. Thus, various differences to mucosal levels in healthy controls have been 
219 reported in some publications [19,23,30] but not in others [21,24,25]. Also of interest to note 
220 was the mucosal TNF as one of the main mediators of IBD [28], was increased in this study 
221 but not in other studies [20,22]. This may be due to methodological differences, especially 
222 considering the low-level increase registered. The TNF-alpha G/A polymorphism at position 
223 308 has been observed in IBS patients [31] and may have pathophysiological role in IBS.  
224      The two TH2 cytokines IL-5 and IL-9 were increased compared to the healthy control 
225 group. Both cytokines secreted from mast cells that has been proposed to be one of the main 
226 mediators of hypersensitivity in IBS [32]. Our IL-5 and IL9 data are in agreement with 
227 previous reports in IBS [33,34]. Therefore, all these data taken together indicate that in IBS a 
228 mucosal TH2 dysregulation exists, which mediates a low-grade inflammation with activation 
229 of inflammatory cells such as mast cells [3,32].
230       The mucosal level of the TH1 chemokine RANTES and eotaxin was significantly 
231 increased in IBS. First, the eotaxin result fits well with the documentation of mast cell 
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232 activation in IBS [16] and the mast cell activation of eotaxin [35]. Moreover, our data agrees 
233 with our findings of increased levels of the TH1 cytokines and TNF as cytokines with strong 
234 effect on activation of chemotaxis. In another report, CXCL-9 and MCP1 were even lower in 
235 IBS than in the healthy controls [22]. These discrepancies are hard to explain. The 
236 chemokines are responsible for the leukocyte migration by creating a chemical gradient from 
237 the vascular endothelium to the infected cells and by selective expressions of different 
238 chemokine receptors on the leukocytes [36]. It is interesting to speculate that a lack of a more 
239 complete and global chemokine response may be one explanation of the lack of a tissue 
240 invasion of leucocytes measured by conventional diagnostic procedures.  
241      Of the various growth factors measured, there were significant increases in the growth 
242 factors bFGF, PDGFBB and GM-CSF. As far as we know there are no previous reports of 
243 these two mucosal growth factors in IBS. Other growth factors such as neural growth factor 
244 has been shown to be overexpressed in intestinal mucosa in IBS [37]. In general, growth 
245 factors play a role to maintain the mucosa integrity [38] are proposed to have anti-
246 inflammatory effects. In chronic inflammation such as in IBD, these mediators play a role in 
247 the mucosal healing. 
248      In IBS patients with self-reported fructose intolerance, only IL-5 was significantly 
249 increased compared to IBS patients without fructose intolerance indicating a possible allergy-
250 like mechanism. The pathophysiological mechanisms behind this condition is unknown, but it 
251 has been proposed to be due to reduced intestinal absorption capacity of fructose [39]. 
252 Whether an allergic mechanism could be involved, has to be further investigated.
253     In general, IBS is most likely a heterogeneous disease where the main proposed 
254 contributing pathophysiological factors are neuroendocrine abnormalities, low grade 
255 inflammation, failure of the gut barrier, increased fecal bile content, abnormal visceral 
256 hypersensitivity and psychosocial stress. Moreover, stress as a causal factor of immune 
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257 dysregulation in the gut has been known for long in animals [40] and in humans (for review, 
258 see [41]. The heterogeneity is supported by the various contradictory reports concerning the 
259 mucosal immunophenotype between our and other reports (for review, see [4,7,42,43]. The 
260 pathophysiological mechanism behind IBS can either be abnormal interactions between 
261 neurons/nerves and immune cells [43], also referred to as the “neuroimmune” synapse [6]. 
262 Moreover, though many of the IBS subjects in the present study show a pro-inflammatory 
263 tendency, a substantial part of the IBS subjects falls within the “normal control” sphere 
264 (figure 1), which underlines the impression that IBS is a disorder of heterogenic pathogenesis. 
265 Finally, we should be aware that the suggested immunological disturbancies in IBS is still 
266 least controversial and described by some as a possible myth [44]. 
267      The strength of this study is the broad mucosal characterization of cytokines, chemokines 
268 and growth factors that would be potentially involved in IBS as an immunological active 
269 disease.  The weakness of the study that should initiate further studies is that whole biopsy 
270 extracts is relatively crude. A mucosal immunologic characterization at cellular level would 
271 give more comprehensive data. Moreover, IBS is most likely a heterogeneous disease 
272 concerning the potential etiological factors and the various clinical phenotypes.  Therefore, 
273 further studies are needed focusing on subgrouping defined by subgroup phenotypes of IBD, 
274 as well as precipitating factors such as infection, stress and antibiotics. Moreover, potentially, 
275 the inflammatory biomarkers could be explained by changes in the fecal microbiota, and 
276 microbiotic phenotypes related to diet including fiber intake [45,46]. This awaits further 
277 studies.
278
279       In conclusion, a dysregulated mucosal immune profile with a mixed TH1, TH2, TH17 and 
280 growth factor profile is observed in IBS patients when compared to healthy control. This 
281 indicates that IBS is a low-grade inflammatory bowel disease with an apparent incomplete 
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282 chemotactic stimulus that may preclude recruitment of leucocytes from the general 
283 circulation.      
284
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425
426 Table 1 










Age (median [range]) 48.5 50 [40  72] 48 [25  62] 59 [35  79] Ns
Female per cent 68 % 63 % 100 % 35 % 0.019#
Abdominal pain/discomfort (mm) 55.2 61 50 0 Ns*
Bloating (mm) 56 63 51 0 Ns*
Stool frequency (median [range]) 1.8 1.6 1.7 1.0 Ns*
Boston scale stool consistency 
(mean [range])
4,6 5.2 3.9 4.0 Ns*
428 FI: Fructose intolerance. FT: fructose tolerance. IBS: Irritable bowel syndrome. # Controls vs 
429 IBS groups; * IBS subgroups compared.
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431 Table 2. Mucosal levels of cytokines, chemokines and growth factors in patients with IBS and 
432 in healthy controls. 
Mediator IBS (N = 42) Normal control (N = 20) P
IFNγ 18 (16 – 20) 14 (12 – 17) 0.010
IL-1β 6.7 (5.6 – 7.9) 4.1 (3.1 – 5.5) 0.004
IL-1RA 1299 (1012 – 1668) 818 (533 – 1254) 0.057
IL-2 0.64 (0.58 – 0.71) 0.39 (0.35 – 0.44) <0.0005
IL-4 0.91 (0.79 – 1.04) 0.71 (0.62 – 0.82) 0.032
IL-5† 0.29 (0.25 – 0.33) 0.33 (0.22 – 0.43) 0.435
IL-6 1.5 (1.1 – 2.0) 1.1 (0.9 – 1.2) 0.136
IL-7 10.7 (9.7 – 11.9) 10.6 (9.2 – 12.2) 0.893
IL-8 24 (16 – 35) 15 (11 – 19) 0.101
IL-9 8.2 (7.2 – 9.2) 6.5 (5.7 – 7.5) 0.040
IL-10 5.5 (4.7 – 6.4) 4.6 (3.8 – 5.5) 0.165
IL-12p70 5.8 (4.9 – 6.9) 5.2 (4.5 – 6.1) 0.404
IL-13 0.85 (0.79 – 0.91) 0.81 (0.73 – 0.90) 0.448
IL-15 2.3 (2.1 – 2.6) 1.7 (1.5 – 1.8) <0.0005
IL-17† 3.2 (2.6 – 3.7) 2.0 (1.6 – 2.4) 0.001*
TNF 160 (143 – 178) 130 (115 – 147) 0.025
Eotaxin 6.7 (5.6 – 7.9) 4.1 (3.1 – 5.5) 0.004
IP-10 590 (437 – 798) 401 (301 – 533) 0.119
MCP1MCA 75 (66 – 86) 71 (60 – 85) 0.647
MIP-1α 3.3 (2.6 – 4.2) 3.0 (2.3 – 4.0) 0.645
MIP-1β 74 (62 – 89) 64 (53 – 77) 0.321
RANTES 2011 (1378 – 2934) 891 (545 – 1454) 0.016
bFGF 674 (596 – 761) 446 (384 – 518) <0.0005
G-CSF 6.4 (5.0 – 8.2) 6.4 (5.2 – 8.0) 0.966
GM-CSF 4.4 (3.8 – 5.1) 2.4 (1.7 – 3.1) <0.0005
PDGFBB 11.7 (9.9 – 13.7) 8.2 (6.1 – 11.1) 0.032
VEGF 160 (130 – 196) 150 (117 – 192) 0.722
433 Values are mean (95% CI of mean) expressed in pg/mL of tissue supernatant. Logarithmic 
434 transformation was applied to obtain Gaussian distribution in all cases except those marked 
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435 with dagger. P-values were generated by independent samples t-test; equality of variances 
436 were observed in all cases except IL17 where the corrected t was used (*).
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438 Figure 1. Principal component analysis of 27-plex mediator measurement in rectal mucosa 
439 from subjects with IBS w/wo fructose intolerance, IBS controls, and normal controls. Three 
440 PC’s were extracted accounting for a cumulated 55% of the variance. The plot shows 
441 individual factor loadings of the two first components in a rotated solution. PC1 (30% 
442 variance) represents an adaptive pro-inflammatory component with high contribution from 
443 mediators like TNF, IFNγ, IL-17, IL-4, and IL-2. PC2 (13% variance) represents an early 
444 response pro-inflammatory component with high contribution from mediators like IL-8, IL-6, 
445 IL-9, bFGF, and MIP-1α. 
446
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Table 1 










Age (median [range]) 48.5 50 [40  72] 48 [25  62] 59 [35  79] Ns
Female per cent 68 % 63 % 100 % 35 % 0.019#
Abdominal pain/discomfort (mm) 55.2 61 50 0 Ns*
Bloating (mm) 56 63 51 0 Ns*
Stool frequency (median [range]) 1.8 1.6 1.7 1.0 Ns*
Boston scale stool consistency 
(mean [range])
4,6 5.2 3.9 4.0 Ns*
FI: Fructose intolerance. FT: fructose tolerance. IBS: Irritable bowel syndrome. # Controls vs 
IBS groups; * IBS subgroups compared.
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Table 2. Mucosal levels of cytokines, chemokines and growth factors in patients with IBS and 
in healthy controls. 
Mediator IBS (N = 42) Normal control (N = 20) P
IFNγ 18 (16 – 20) 14 (12 – 17) 0.010
IL-1β 6.7 (5.6 – 7.9) 4.1 (3.1 – 5.5) 0.004
IL-1RA 1299 (1012 – 1668) 818 (533 – 1254) 0.057
IL-2 0.64 (0.58 – 0.71) 0.39 (0.35 – 0.44) <0.0005
IL-4 0.91 (0.79 – 1.04) 0.71 (0.62 – 0.82) 0.032
IL-5† 0.29 (0.25 – 0.33) 0.33 (0.22 – 0.43) 0.435
IL-6 1.5 (1.1 – 2.0) 1.1 (0.9 – 1.2) 0.136
IL-7 10.7 (9.7 – 11.9) 10.6 (9.2 – 12.2) 0.893
IL-8 24 (16 – 35) 15 (11 – 19) 0.101
IL-9 8.2 (7.2 – 9.2) 6.5 (5.7 – 7.5) 0.040
IL-10 5.5 (4.7 – 6.4) 4.6 (3.8 – 5.5) 0.165
IL-12p70 5.8 (4.9 – 6.9) 5.2 (4.5 – 6.1) 0.404
IL-13 0.85 (0.79 – 0.91) 0.81 (0.73 – 0.90) 0.448
IL-15 2.3 (2.1 – 2.6) 1.7 (1.5 – 1.8) <0.0005
IL-17† 3.2 (2.6 – 3.7) 2.0 (1.6 – 2.4) 0.001*
TNF 160 (143 – 178) 130 (115 – 147) 0.025
Eotaxin 6.7 (5.6 – 7.9) 4.1 (3.1 – 5.5) 0.004
IP-10 590 (437 – 798) 401 (301 – 533) 0.119
MCP1MCA 75 (66 – 86) 71 (60 – 85) 0.647
MIP-1α 3.3 (2.6 – 4.2) 3.0 (2.3 – 4.0) 0.645
MIP-1β 74 (62 – 89) 64 (53 – 77) 0.321
RANTES 2011 (1378 – 2934) 891 (545 – 1454) 0.016
bFGF 674 (596 – 761) 446 (384 – 518) <0.0005
G-CSF 6.4 (5.0 – 8.2) 6.4 (5.2 – 8.0) 0.966
GM-CSF 4.4 (3.8 – 5.1) 2.4 (1.7 – 3.1) <0.0005
PDGFBB 11.7 (9.9 – 13.7) 8.2 (6.1 – 11.1) 0.032
VEGF 160 (130 – 196) 150 (117 – 192) 0.722
Values are mean (95% CI of mean) expressed in pg/mL of tissue supernatant. Logarithmic 
transformation was applied to obtain Gaussian distribution in all cases except those marked 
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with dagger. P-values were generated by independent samples t-test; equality of variances 
were observed in all cases except IL17 where the corrected t was used (*).
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Figure 1. Principal component analysis of 27-plex mediator measurement in rectal mucosa 
from subjects with IBS w/wo fructose intolerance, IBS controls, and normal controls. Three 
PC’s were extracted accounting for a cumulated 55% of the variance. The plot shows 
individual factor loadings of the two first components in a rotated solution. PC1 (30% 
variance) represents an adaptive pro-inflammatory component with high contribution from 
mediators like TNF, IFNγ, IL-17, IL-4, and IL-2. PC2 (13% variance) represents an early 
response pro-inflammatory component with high contribution from mediators like IL-8, IL-6, 
IL-9, bFGF, and MIP-1α. 
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Intestinal inflammatory profile shows increase in a diversity of biomarkers in 
irritable bowel syndrome 
Page 55 of 55
http://mc.manuscriptcentral.com/gastro Email: IGAS-peerreview@journals.tandf.co.uk
Scandinavian Journal of Gastroenterology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
